Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1‒mediated inhibition of the PI3K/AKT pathway

Read full text Summarise with VIRAT
Authors: Jiale Xu, Xiaoyu Qin, Longying Xiong, Cheng Zhao, Dan Ge, Yanping Wu, Yixuan Shen, Mengli Yang, Bihan Shen, Min Chen, Chen Min
Cited by: 0
References: 46

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

As a hydroxymethylglutaryl‒coenzyme A reductase (HMGCR) inhibitors, atorvastatin (ATST) has garnered widespread attention because of its antitumor effects. However, its specific mechanism of action remains incompletely understood. In our study, ATST was found to inhibit AOM/DSS‒induced colorectal cancer (CRC) progression in mice. Mechanistically, by inhibiting HMGCR and depleting cellular cholesterol, ATST activates the SREBP2‒FDFT1 axis. This in turn inhibits the PI3K/AKT pathway, inducing endoplasmic reticulum (ER) stress and autophagy while concurrently promoting lipid catabolism to drive ferroptosis. This study elucidates the mechanism through which ATST regulates lipid catabolism to influence CRC progression, providing a new direction for CRC therapy.

Fields of Study & Subjects

Cancer Lipids and Metabolism Ferroptosis and cancer prognosis Cholesterol and Lipid Metabolism

Publication details

Journal / source
Cell Communication and Signaling
Volume
24
Issue
1
Publication date
23 March 2026
Language
EN